Gösterilen 1 - 9 sonuçlar arası kayıtlar. 9 sonuç. Aranan kelime 'Ruth Plummer (15028641)', Sorgu süresi: 0.01s Sonuçları Daraltın
  1. 1
    Figure 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

    Figure 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors Yazar: Kristoffer Staal Rohrberg (15009138)

    Baskı/Yayın Bilgisi 2025
    Diğer Yazarlar:
    Favorilerime ekle
    Kaydedildi:
  2. 2
    Figure 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

    Figure 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors Yazar: Kristoffer Staal Rohrberg (15009138)

    Baskı/Yayın Bilgisi 2025
    Diğer Yazarlar:
    Favorilerime ekle
    Kaydedildi:
  3. 3
    Table 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

    Table 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors Yazar: Kristoffer Staal Rohrberg (15009138)

    Baskı/Yayın Bilgisi 2025
    Diğer Yazarlar:
    Favorilerime ekle
    Kaydedildi:
  4. 4
    Table 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

    Table 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors Yazar: Kristoffer Staal Rohrberg (15009138)

    Baskı/Yayın Bilgisi 2025
    Diğer Yazarlar:
    Favorilerime ekle
    Kaydedildi:
  5. 5
    Figure S1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

    Figure S1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors Yazar: Kristoffer Staal Rohrberg (15009138)

    Baskı/Yayın Bilgisi 2025
    Diğer Yazarlar:
    Favorilerime ekle
    Kaydedildi:
  6. 6
    Table 4 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

    Table 4 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors Yazar: Kristoffer Staal Rohrberg (15009138)

    Baskı/Yayın Bilgisi 2025
    Diğer Yazarlar:
    Favorilerime ekle
    Kaydedildi:
  7. 7
    Table 3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

    Table 3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors Yazar: Kristoffer Staal Rohrberg (15009138)

    Baskı/Yayın Bilgisi 2025
    Diğer Yazarlar:
    Favorilerime ekle
    Kaydedildi:
  8. 8
    Figure S2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

    Figure S2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors Yazar: Kristoffer Staal Rohrberg (15009138)

    Baskı/Yayın Bilgisi 2025
    Diğer Yazarlar:
    Favorilerime ekle
    Kaydedildi:
  9. 9
    Figure S3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

    Figure S3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors Yazar: Kristoffer Staal Rohrberg (15009138)

    Baskı/Yayın Bilgisi 2025
    Diğer Yazarlar:
    Favorilerime ekle
    Kaydedildi:

Arama Araçları: